[go: up one dir, main page]

WO2010006286A3 - Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps - Google Patents

Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps Download PDF

Info

Publication number
WO2010006286A3
WO2010006286A3 PCT/US2009/050290 US2009050290W WO2010006286A3 WO 2010006286 A3 WO2010006286 A3 WO 2010006286A3 US 2009050290 W US2009050290 W US 2009050290W WO 2010006286 A3 WO2010006286 A3 WO 2010006286A3
Authority
WO
WIPO (PCT)
Prior art keywords
light chain
libraries
constructs
chain sequences
kappa light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/050290
Other languages
English (en)
Other versions
WO2010006286A2 (fr
Inventor
Lawrence Horowitz
Ramesh R. Bhatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sea Lane Biotechnologies LLC
Original Assignee
Sea Lane Biotechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2729181A priority Critical patent/CA2729181A1/fr
Priority to CN2009801348404A priority patent/CN102149727A/zh
Priority to BRPI0915512A priority patent/BRPI0915512A2/pt
Priority to MX2011000230A priority patent/MX2011000230A/es
Priority to AU2009268352A priority patent/AU2009268352A1/en
Priority to EP09790293A priority patent/EP2300498A2/fr
Application filed by Sea Lane Biotechnologies LLC filed Critical Sea Lane Biotechnologies LLC
Priority to JP2011517662A priority patent/JP2011527707A/ja
Publication of WO2010006286A2 publication Critical patent/WO2010006286A2/fr
Publication of WO2010006286A3 publication Critical patent/WO2010006286A3/fr
Priority to IL210052A priority patent/IL210052A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des constructions et bibliothèques comprenant des séquences à chaîne légère de K succédané d'anticorps. En particulier, l'invention concerne des constructions contenant des séquences à chaîne légère de kappa succédané d'anticorps, facultativement liés avec un autre polypeptide, comme par exemple des séquences de domaine à chaîne légère et/ou lourde d'anticorps, et des bibliothèques les contenant.
PCT/US2009/050290 2008-07-11 2009-07-10 Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps Ceased WO2010006286A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2009801348404A CN102149727A (zh) 2008-07-11 2009-07-10 包含抗体替代卡帕轻链序列的构建体和文库
BRPI0915512A BRPI0915512A2 (pt) 2008-07-11 2009-07-10 construtos e bibliotecas compreendendo sequências substitutas de cadeia leve kappa de anticorpo
MX2011000230A MX2011000230A (es) 2008-07-11 2009-07-10 Construcciones y bibliotecas que comprenden secuencias de cadena ligera kappa surrogadas de anticuerpo.
AU2009268352A AU2009268352A1 (en) 2008-07-11 2009-07-10 Constructs and libraries comprising antibody surrogate kappa light chain sequences
EP09790293A EP2300498A2 (fr) 2008-07-11 2009-07-10 Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps
CA2729181A CA2729181A1 (fr) 2008-07-11 2009-07-10 Constructions et bibliotheques comprenant des sequences a chaine legere de kappa succedane d'anticorps
JP2011517662A JP2011527707A (ja) 2008-07-11 2009-07-10 抗体代替κ軽鎖配列を含む構築物及びライブラリー
IL210052A IL210052A0 (en) 2008-07-11 2010-12-16 Constructs and libraries comprising antibody surrogate kappa light chain sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13492908P 2008-07-11 2008-07-11
US61/134,929 2008-07-11

Publications (2)

Publication Number Publication Date
WO2010006286A2 WO2010006286A2 (fr) 2010-01-14
WO2010006286A3 true WO2010006286A3 (fr) 2010-05-27

Family

ID=41507761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/050290 Ceased WO2010006286A2 (fr) 2008-07-11 2009-07-10 Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps

Country Status (11)

Country Link
US (1) US20100062950A1 (fr)
EP (1) EP2300498A2 (fr)
JP (1) JP2011527707A (fr)
KR (1) KR20110028543A (fr)
CN (1) CN102149727A (fr)
AU (1) AU2009268352A1 (fr)
BR (1) BRPI0915512A2 (fr)
CA (1) CA2729181A1 (fr)
IL (1) IL210052A0 (fr)
MX (1) MX2011000230A (fr)
WO (1) WO2010006286A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132312B1 (fr) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
CA2761681A1 (fr) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Molecules neutralisantes dirigees contre les virus de la grippe
TWI560271B (en) 2009-06-26 2016-12-01 Sealane Biotechnologies Llc Expression of surrogate light chains
US20120269830A1 (en) * 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
WO2013003652A1 (fr) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Protéines de liaison à domaines variables empilés polyvalentes
EP2736928B1 (fr) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3
WO2013096828A1 (fr) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Protéines substitutives de liaison
WO2013109994A1 (fr) 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Conjugués surrobody
CA2944647C (fr) 2014-04-03 2025-07-08 Igm Biosciences Inc Chaîne j modifiée
JP2018507254A (ja) 2015-02-02 2018-03-15 アイツー ファーマシューティカルズ， インコーポレーテッド 抗代替軽鎖抗体
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2022177918A1 (fr) 2021-02-16 2022-08-25 Children's Health Care D/B/A Children's Minnesota Méthodes de traitement de b-all par administration d'un antagoniste de complexe pre-bcr

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068696A1 (fr) * 2000-03-15 2001-09-20 Incyte Genomics, Inc. Proteines de reponse immunitaire humaines
WO2008118970A2 (fr) * 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476198B1 (en) * 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068696A1 (fr) * 2000-03-15 2001-09-20 Incyte Genomics, Inc. Proteines de reponse immunitaire humaines
WO2008118970A2 (fr) * 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 7 November 1985 (1985-11-07), "Human germ line gene for immunoglobulin kappa light chain leader peptide and variable region (subgroup V kappa I)", XP002570437, retrieved from EBI accession no. EMBL:V01577 Database accession no. V01577 *
FRANCES VERONIQUE ET AL: "A surrogate 15 kDa JC-kappa protein is expressed in combination with mu heavy chain by human B cell precursors", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 24, 1 August 1994 (1994-08-01), pages 5937 - 5943, XP009130092, ISSN: 0261-4189 *
MCKELLER M R ET AL: "The kappa-like pre-B receptor: Surplus biology or a missing link?", SEMINARS IN IMMUNOLOGY, W.B. SAUNDERS COMPANY, PA, US, vol. 18, no. 1, 1 February 2006 (2006-02-01), pages 40 - 43, XP024907985, ISSN: 1044-5323, [retrieved on 20060201] *
MORSTADT LUCIA ET AL: "Engineering and characterization of a single chain surrogate light chain variable domain", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 17, no. 3, 1 March 2008 (2008-03-01), pages 458 - 465, XP009106641, ISSN: 0961-8368 *
RANGEL ROBERTO ET AL: "Assembly of the kappa PreB receptor requires a V kappa-like protein encoded by a germline transcript", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 280, no. 18, 1 May 2005 (2005-05-01), pages 17807 - 17814, XP009130089, ISSN: 0021-9258 *
THOMPSON ALLAN ET AL: "A pro-B-cell stage characterized by germline lg transcription without surrogate light chain expression", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 48, no. 5, 1 October 1998 (1998-10-01), pages 305 - 311, XP009130088, ISSN: 0093-7711 *
XU LI ET AL: "Combinatorial surrobody libraries", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 105, no. 31, 5 August 2008 (2008-08-05), pages 10756 - 10761, XP002498064, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2011527707A (ja) 2011-11-04
BRPI0915512A2 (pt) 2017-06-20
WO2010006286A2 (fr) 2010-01-14
KR20110028543A (ko) 2011-03-18
AU2009268352A1 (en) 2010-01-14
CN102149727A (zh) 2011-08-10
MX2011000230A (es) 2011-03-02
EP2300498A2 (fr) 2011-03-30
CA2729181A1 (fr) 2010-01-14
US20100062950A1 (en) 2010-03-11
IL210052A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
WO2008118970A3 (fr) Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
WO2010006286A3 (fr) Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps
WO2010011944A3 (fr) Procédés de criblage de protéines
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
PH12013501101A1 (en) Immunosuppressive polypeptides and nucleic acids
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
IL212100A0 (en) Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
WO2009140039A3 (fr) Anticorps synthétiques
WO2008063776A3 (fr) Anticorps de la lymphotoxine-alpha
WO2009100309A3 (fr) Anticorps anti-ifnar1 ayant une affinité réduite pour le ligand fc
IL205127A (en) Antibody to aβ is humanized, a preparation containing it and its uses
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
WO2008048970A8 (fr) Anticorps synthétiques
WO2006105338A3 (fr) Variants fc presentant des proprietes optimisees
WO2009130479A3 (fr) Virus
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2010027642A3 (fr) Sélection de molécules interagissant de façon coopérative
WO2006098998A3 (fr) Procedes et compositions de modulation de l'integrite vasculaire
NL1034283A1 (nl) Laadwagen.
NL2001964A1 (nl) Laadwagen.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980134840.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09790293

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009268352

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 210052

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2729181

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011517662

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/000230

Country of ref document: MX

Ref document number: 2009790293

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009268352

Country of ref document: AU

Date of ref document: 20090710

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117003119

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0915512

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110110